Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Lack of Association Between MIF Gene -173G>C Polymorphism with Multiple Sclerosis

BETUL CEVIK, SERBULENT YIGIT, NEVIN KARAKUS, DURDANE AKSOY, OMER ATES and SEMİHA KURT
In Vivo January 2015, 29 (1) 71-76;
BETUL CEVIK
1Gaziosmanpasa University Faculty of Medicine, Department of Neurology, Tokat, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cevikbetul78@hotmail.com
SERBULENT YIGIT
2Gaziosmanpasa University Faculty of Medicine, Department of Medical Biology, Tokat, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NEVIN KARAKUS
2Gaziosmanpasa University Faculty of Medicine, Department of Medical Biology, Tokat, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DURDANE AKSOY
1Gaziosmanpasa University Faculty of Medicine, Department of Neurology, Tokat, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OMER ATES
2Gaziosmanpasa University Faculty of Medicine, Department of Medical Biology, Tokat, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEMİHA KURT
1Gaziosmanpasa University Faculty of Medicine, Department of Neurology, Tokat, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: The aim of the present study was to investigate a possible association between the MIF -173G>C polymorphism and MS in Turkish patients. Materials and Methods: The study included 153 MS-patients and 210 controls. Genomic DNA was isolated and genotyped using PCR-RFLP assay for the MIF -173G>C promoter polymorphism (rs755622). Results: There was no statistically significant difference in allele and genotype frequencies between MS-patients and controls (p=0.227 and p=0.157, respectively). Accordingly, no association was observed when the patients were compared against controls in terms of GG versus GC+CC genotypes and GG+GC versus CC genotypes (p=0.324 and p=0.179, respectively). Also, there was no statistically significant association between MIF-173G>C polymorphism and clinical and demographic characteristics of MS-patients. Conlusion: The results of the present study suggest no relation between MS susceptibility and MIF gene - 173G>C polymorphism in the examined Turkish population.

  • Multiple sclerosis
  • susceptibility
  • macrophage migration inhibitory factor (MIF)
  • -173G>C gene polymorphism
  • promoter polymorphism

Multiple sclerosis (MS) is a chronic, neurodegenerative autoimmune disease of the central nervous system (CNS) characterized by areas of inflammation, demyelination and axonal damage (1). MS affects around 2.5 million people worldwide, 80-85% of whom are diagnosed with a relapsing-remitting (RR) form of the disease. It typically affects young adults and leads to significant physical and cognitive disabilities (1, 2). MS is triggered by environmental factors in individuals with complex genetic-risk profiles. Although the human leukocyte antigen region is the first and major genetic risk factor, genome-wide association studies identified new susceptibility genes including some cytokine genes (3).

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that plays a critical role in the regulation of macrophage effector functions and T-cell activation (4). Human MIF gene is located on chromosome 22q11.2. The MIF -173G>C (rs755622) (a guanine-to-cytosine transition at position-173 of the MIF gene) polymorphism is located in the promoter region, and has been indicated to correlate with increased MIF production both in vitro and in vivo (5). Elevated levels of MIF have been observed in the cerebrospinal fluid (CSF) and sera of MS patients during relapses, and a number of lymphocytes strongly-expressing MIF infiltrate into the pathogenic lesions (MS plaques) (7-9). Recently, anti-MIF treatments of mice with experimental autoimmune encephalomyelitis (EAE), an animal model of MS, improved disease severity and accelerated recovery (9, 10). These results suggest that MIF plays a critical role in the physiopathology of the MS. MIF -173G>C polymorphism has been associated with disease course and susceptibility to various inflammatory and autoimmune diseases such as rheumatoid arthritis (11), juvenile idiopathic arthritis (12), sarcoidosis (13), psoriasis (14), scleroderma (15), glomerulonephritis (16), asthma (17), and inflammatory bowel disease (18) in various populations. All these data may suggest a novel genetic association with autoimmune disorders and MIF -173G>C polymorphism. Since certain cytokine gene polymorphisms are known to influence susceptibility to, and clinical phenotype of MS (19), we designed a case-control study to investigate the possible association between the MIF gene -173G>C polymorphism and susceptibility and/or clinical features of MS in a Turkish population.

Patients and Methods

Subjects. The study population comprised of 153 unrelated patients (45 males and 108 females; mean age (±SD)=36.84±9.412 years) with a clinical diagnosis of MS recruited consecutively and prospectively from those who were treated and followed-up in the Neurology Department of Gaziosmanpasa University Research Hospital, Tokat, Turkey. The diagnosis of MS was based on the 2005 Revised McDonald Multiple Sclerosis criteria for classification (20). A total of 210 unrelated healthy subjects (80 male and 130 female; mean age=36.36±10.933 SD years) were recruited consecutively. All participants, patients and healthy controls, were of Turkish origin, from inner Central Black Sea region of Turkey. The healthy controls matched for age and gender with MS patients (p=0.658 and p=0.094, respectively) (Table I) and free from another inflammatory-demyelinating disease. The protocol of this study was approved by the Institutional Ethics Committee and all participants gave their written informed consent before entering the study.

Genotyping. Genomic DNA was extracted from whole venous blood samples using a commercial DNA isolation kit (Sigma-Aldrich, Taufkirchen, Germany). The MIF -173G>C promoter polymorphism (rs755622) was analyzed by polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) assay as described previously (21). The sequences of forward and reverse PCR primers were 5’-ACT AAG AAA GAC CCG AGG C-3’ and 5’-GGG GCA CGT TGG TGT TTA C -3’, respectively. After amplification, the 366 bp PCR product was digested with AluI in a 15 μl reaction solution containing 10 μl of PCR product, 1.5 μl of 10× buffer, and three units of AluI at 37°C overnight. The digestion products were separated on 3% agarose gels, and fragments stained with the ethidium bromide were photographed on an ultraviolet transilluminator. 2 fragments (268 and 97 bp) were seen when G allele was present at position -173 and 3 fragments (206, 97, and 62 bp) when C allele was present.

Statistical analysis. Statistical analysis was performed by using the Statistical Package Program for the Social Sciences (IBM SPSS, version 2.0) and the OpenEpi Info software package version 3.01 (www.openepi.com). Results were expressed as mean±SD. The chi-square (χ2) test was used to evaluate the Hardy-Weinberg equilibrium for the distribution of the genotypes of the patients and the controls. The relationships between MIF -173G>C polymorphism and the clinical and demographic characteristics of patients were analyzed by using χ2 test, Fischer exact test or analysis of variance (ANOVA) statistics. Odds ratio (OR) and 95% confidence interval (CI) were used for the assessment of risk factors. All p-values were 2-tailed and p-values less than 0.05 were considered as significant.

Results

The baseline clinical and demographic characteristics of the study patients with MS stratified according to MIF gene -173G>C polymorphism are shown in Table II. Gender, age, age of onset, disease duration, EDSS (expanded disability status scale) score, frequency of attacks, number of lesions on magnetic resonance imaging and family history of MS patients were analyzed and no statistically significant association was observed between clinical and demographic characteristics of MS patients and MIF gene -173G>C polymorphism (Table II). We also analyzed the probability of MS patients to reach an EDSS score of 3 or 6 during the disease course in relation to the -173G>C polymorphism and no association was found (Table II). Allelic and genotypic distributions of the MIF gene -173G>C polymorphism in patients and controls are shown in Table III. The genotype and allele frequencies of -173G>C polymorphism did not show any statistically significant differences between MS patients and controls (p=0.227 and p=0.157 OR=0.74, 95%CI=0.48-1.12, respectively). Also, no significant association was observed when the patients were compared with the controls according to GG genotype versus GC+CC genotypes and GG+GC versus CC genotypes (p=0.324 and p=0.179, respectively). Results of the present study suggest no relation between MS susceptibility and MIF gene -173G>C polymorphism in the present Turkish population. The observed and expected frequencies of the polymorphism in both patient and control groups were in Hardy-Weinberg equilibrium.

Discussion

Although the etiopathology of MS remains unknown, it is considered to trigger an inflammatory cascade resulting in axonal and neuronal degeneration in CNS induced by myelin-reactive CD4+ T-lymphocytes crossing the blood-brain barrier after being activated in peripheral tissues (2, 9). The initial phase of the disease includes adaptive immunity and CD4+ T-helper (Th)1, Th-17 and CD8+ T-cells, all of which are modulated by T-regulator, CD4+ Th2, B cells, macrophages, microglia and natural killer cells. On the other hand, disease progression includes the innate immunity (22). MIF is a pleiotropic pro-inflammatory cytokine involved in the regulation of both innate and adaptive immunity (23). It is mainly secreted by activated T-lymphocytes and monocyte/macrophages, up-regulates the pro-inflammatory actions of these cells, and stimulates them to produce a wide range of pro-inflammatory molecules that play a vital role in the MS pathogenesis, including interleukin (IL)-1beta, IL-6, IL-8, interferon-gamma, tumor necrosis factor-alfa, prostaglandin E2, nitric oxide, cytosolic phospholipase A2 and cyclooxygenase-2 (23-26). MIF inhibits the random migration of macrophages, concentrating macrophages at the inflammatory site and it is thought to play an important role in cell-mediated immunity. In addition, MIF enhances Toll-like receptor-4 expression on the macrophage surface, increases phagocytosis and intracellular killing. It up-regulates the expression of intracellular adhesion molecule-1 and vascular cell adhesion molecule-1, and matrix metalloproteinases, leading to enhanced blood-brain barrier permeability (10, 23, 24, 27). Thus, MIF induces the accumulation of neuroantigen-reactive T-cells and other inflammatory cells in the CNS, facilitating the development of EAE and MS. MIF reduces the population of regulatory T-cells, which suppresses the immune functions of other cells, allowing inflammation in the context of MS in both the brain and spinal cord (4, 10). Furthermore, it inhibits p53-dependent apoptosis of lymphocytes and macrophages. A failure of autoreactive T-cells to undergo apoptosis due to higher levels of MIF expression may lead to inappropriate persistence of these cells and cause harmful immunoreactivity in MS (8, 10). MIF also stimulates the antibody production in B-cells, which have been demonstrated to exhibit clonal enlargement (22). As a neuro-endocrine mediator, MIF is secreted by anterior pituitary cells and counter-regulates the immunosuppressive and anti-inflammatory actions of glucocorticoids. Hence, genetic predisposition to higher MIF production may increase the magnitude, duration and possibly the chronicity of immune and inflammatory responses (5, 27, 28).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

The demographic characteristics of MS patients and healthy controls.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Clinical and demographic characteristics of patients stratified according to MIF gene -173G>C polymorphism.

MIF is necessary for the progression of EAE but is not required for initial activation of auto-reactive lymphocytes. It has been demonstrated that the detection of infiltrating monocytes in the CNS of EAE mice is correlated with substantial clinical disability (10, 29). MIF synthesis is known to be significantly increased in active MS plaques constituted mainly by T lymphocytes, macrophages and microglia (9, 10). To further implicate a role for MIF in MS, Denkinger et al. (4) have demonstrated that anti-MIF treatment in mice with acute EAE decreases accumulation of encephalitogenic T-cells and other inflammatory cells into the CNS and expands a population of regulatory T lymphocytes, reducing the severity of clinical signs and accelerating recovery from the disease. It has also been suggested that inhibition of MIF reduces relapses of disease in a relapsing/remitting model of EAE (10). MIF levels have been found to increase in the CSF and sera/blood of patients with active/relapsed multiple sclerosis and have therefore been associated with the disease activity (7, 8, 30, 31). Measurement of MIF levels in healthy subjects and in patients with auto-immune inflammatory diseases, such as rheumatoid arthritis and juvenile idiopathic arthritis showed that serum and tissue MIF levels are significantly higher in MIF gene -173*C allele carriers than in MIF -173GG homozygous subjects. Increasing data from literature have linked MIF gene -173G>C polymorphism with susceptibility to or severity and outcome of inflammatory and/or autoimmune diseases, in which increased systemic or local MIF concentrations have been associated with severe clinical manifestations, high severity scores, and often poor outcome (6, 12, 28). These findings suggest that MIF may be a common risk gene for a number of autoimmune disorders. Therefore, we assumed that the MIF gene -173G>C polymorphism may be also associated with MS. To validate the hypotheses, we examined the association of MIF - 173G>C polymorphism with MS and found that allele and genotype frequencies of this polymorphism do not show any statistically significant difference between MS patients and controls. There was no significant association observed when the patients were compared with the controls according to GG genotype versus GC+CC genotypes and GG+GC versus CC genotypes (Table III). Also, there as no statistically significant association between MIF -173G>C polymorphism and baseline clinical and demographic characteristics of MS patients (Table II). Our findings conflict with the previous data reported by Akcali et al. (32). In that study including 120 RRMS patients and 120 control subjects from Turkish population, MIF-173 CC and GG genotypes were found to be statistically higher and lower in MS patients, respectively (p<0.001 and p=0.004, respectively). Moreover, patients with the MIF-173 CC genotype had a significantly lower age of disease onset compared to those with the MIF-173 CG and MIF -173GG genotypes. In the study of Akcali et al. on MIF-173 gene polymorphism frequencies, GG genotype was 37% vs. 55%, GC genotype was 43% vs. 41%, and CC genotype was 20% vs. 4.2% in MS patients vs. control subjects, respectively. In the present study, the frequency of GG genotype was 75.2% vs. 70.5%, GC genotype was 23.5% vs. 25.2%, and CC genotype was 1.3% vs. 4.3%. There is a remarkable difference between these two groups in terms of genotype and allele frequencies of MIF gene -173G>C polymorphism. One possible explanation for the conflicting results of the previous report could be the population heterogeneity. Because the study of Akcali et al. and the present study included individuals from the Southeastern Anatolia vs. Central Black Sea regions, conflicting results might be attributed to the differences between these two populations or unknown genetic variations.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Genotype and allele frequencies of -173G>C polymorphism of MIF gene in patient and control groups.

The etiology of MS is complex and includes the interaction of multiple environmental and genetic factors. Both genetic and environmental factors may affect disease susceptibility and phenotypic characteristics, but we cannot not yet understand their exact roles. Among the environmental factors most commonly emphasized factors are the Epstein-Barr virus presence, vitamin D deficiency, ultraviolet exposure and smoking. MS is a polygenic inherited disease. Because the odds ratio for the many genes out of HLA region –the major risk factor for MS- is very low, the size of data set needed for finding an association increases, decreasing the importance of a single gene in genetic predisposition to MS. All these facts can explain the negative association found between MS and MIF -173G>C polymorphism in the present study (22). On the other hand, although MIF -173G>C polymorphism is considered as a risk factor for many inflammatory and autoimmune diseases, studies on some inflammatory and autoimmune diseases such as giant cell arthritis and cutaneous vasculitis have failed to find an association (33, 34). This suggests that the physiopathological processes may vary between autoimmune diseases and that we may have not understood/identified the effects/roles of the MIF and MIF gene polymorphisms in inflammatory diseases completely. The present study suffers several limitations; the sample size was small, which may result in false-positive and false-negative results in genetic association studies by decreasing the statistical power of the study. Moreover, another limitation was the fact that serum and/or CSF MIF levels were not measured in the patient and control groups.

In conclusion, the results of the present study suggest that MIF gene -173G>C promoter polymorphism is not associated with MS susceptibility or clinical presentation in the present Turkish population, but our study has a preliminary character and should be extended on a larger population.

  • Received October 5, 2014.
  • Revision received November 5, 2014.
  • Accepted November 5, 2014.
  • Copyright © 2015 The Author(s). Published by the International Institute of Anticancer Research.

References

  1. ↵
    1. Compston A,
    2. Coles A
    : Multiple sclerosis. Lancet 372(9648): 1502-1517, 2008.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Haussleiter IS,
    2. Brüne M,
    3. Juckel G
    : Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment. Ther Adv Neurol Disord 2(1): 13-29, 2009.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Goris A,
    2. Pauwels I,
    3. Dubois B
    : Progress in multiple sclerosis genetics. Curr Genomics 13(8): 646-663, 2012.
    OpenUrlPubMed
  4. ↵
    1. Denkinger CM,
    2. Denkinger M,
    3. Kort JJ,
    4. Metz C,
    5. Forsthuber TG
    : In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 170(3): 1274-1282, 2003.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Lao W,
    2. Xiang Y,
    3. Fang M,
    4. Yang X
    : Polymorphism and expression of macrophage migration inhibitory factor does not contribute to glucocorticoid resistance in idiopathic thrombocytopenic purpura. Pharmazie 68(10): 846-849, 2013.
    OpenUrlPubMed
  6. ↵
    1. Sreih A,
    2. Ezzeddine R,
    3. Leng L,
    4. LaChance A,
    5. Yu G,
    6. Mizue Y,
    7. Subrahmanyan L,
    8. Pons-Estel BA,
    9. Abelson AK,
    10. Gunnarsson I,
    11. Svenungsson E,
    12. Cavett J,
    13. Glenn S,
    14. Zhang L,
    15. Montgomery R,
    16. Perl A,
    17. Salmon J,
    18. Alarcón-Riquelme ME,
    19. Harley JB,
    20. Bucala R
    : Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 63(12): 3942-3951, 2011.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Niino M,
    2. Ogata A,
    3. Kikuchi S,
    4. Tashiro K,
    5. Nishihira J
    : Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease. J Neurol Sci 179(S 1-2): 127-131, 2000.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Rinta S,
    2. Kuusisto H,
    3. Raunio M,
    4. Paalavuo R,
    5. Levula M,
    6. Lehtimäki T,
    7. Elovaara I
    : Apoptosis-related molecules in blood in multiple sclerosis. J Neuroimmunol 205(1-2): 135-141, 2008.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Bhasin M,
    2. Wu M,
    3. Tsirka SE
    : Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis BMC Immunol 8(10): 1-16, 2007.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kithcart AP,
    2. Cox GM,
    3. Sielecki T,
    4. Short A,
    5. Pruitt J,
    6. Papenfuss T,
    7. Shawler T,
    8. Gienapp I,
    9. Satoskar AR,
    10. Whitacre CC
    : A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J 24(11): 4459-4466, 2010.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Xie Q,
    2. Wang SC,
    3. Bian G,
    4. Zhan FL,
    5. Xie JK,
    6. Li J
    : Association of MIF -173G/C and MBL2 codon 54 gene polymorphisms with rheumatoid arthritis: a meta-analysis. Hum Immunol 73(9): 966-971, 2012.
    OpenUrlPubMed
  12. ↵
    1. Lee YH,
    2. Bae SC,
    3. Song GG
    : The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis. Inflamm Res 61(5): 411-415, 2012.
    OpenUrlPubMed
  13. ↵
    1. Karakaya B,
    2. van Moorsel CH,
    3. van der Helm-van Mil AH,
    4. Huizinga TW,
    5. Ruven HJ,
    6. van der Vis JJ,
    7. Grutters JC
    : Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in Löfgren's syndrome. Cytokine 69(2): 272-276, 2014.
    OpenUrlPubMed
  14. ↵
    1. Wu J,
    2. Chen F,
    3. Zhang X,
    4. Li Y,
    5. Ma H,
    6. Zhou Y,
    7. Jin Y,
    8. Wang H,
    9. Bai J,
    10. Zhang G,
    11. Fu S
    : Association of MIF promoter polymorphisms with psoriasis in a Han population in northeastern China. J Dermatol Sci 53(3): 212-215, 2009.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Wu SP,
    2. Leng L,
    3. Feng Z,
    4. Liu N,
    5. Zhao H,
    6. McDonald C,
    7. Lee A,
    8. Arnett FC,
    9. Gregersen PK,
    10. Mayes MD,
    11. Bucala R
    : Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 54: 3661-3669, 2006.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Berdeli A,
    2. Mir S,
    3. Ozkayin N,
    4. Serdaroglu E,
    5. Tabel Y,
    6. Cura A
    : Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol 20(11): 1566-1571, 2005.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Mizue Y,
    2. Ghani S,
    3. Leng L,
    4. McDonald C,
    5. Kong P,
    6. Baugh J,
    7. Lane SJ,
    8. Craft J,
    9. Nishihira J,
    10. Donnelly SC,
    11. Zhu Z,
    12. Bucala R
    : Role for macrophage migration inhibitory factor in asthma. Pro Natl Acad Sci USA 102: 14410-14415, 2005.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Przybyłowska K,
    2. Mrowicki J,
    3. Sygut A,
    4. Narbutt P,
    5. Dziki Ł,
    6. Dziki A,
    7. Majsterek I
    : Contribution of the -173 G/C polymorphism of macrophage migration inhibitory factor gene to the risk of inflammatory bowel diseases. Pol Przegl Chir 83(2): 76-80, 2011.
    OpenUrlPubMed
  19. ↵
    1. Oksenberg JR,
    2. Baranzini SE,
    3. Sawcer S,
    4. Hauser SL
    : The genetics of multiple sclerosis: SNPs to pathways to pathogenesis.Nat Rev Genet 9(7): 516-526, 2008.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Polman CH,
    2. Reingold SC,
    3. Edan G,
    4. Filippi M,
    5. Hartung HP,
    6. Kappos L,
    7. Lublin FD,
    8. Metz LM,
    9. McFarland HF,
    10. O'Connor PW,
    11. Sandberg-Wollheim M,
    12. Thompson AJ,
    13. Weinshenker BG,
    14. Wolinsky JS
    : Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6): 840-846, 2005.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Wang FF,
    2. Huang XF,
    3. Shen N,
    4. Leng L,
    5. Bucala R,
    6. Chen SL,
    7. Lu LJ
    : A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease. Arthritis Res Ther 15(3): R65, 2013.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Stadelmann C,
    2. Wegner C,
    3. Brück W
    : Inflammation, demyelination, and degeneration – recent insights from MS pathology. Biochim Biophys Acta 1812(2): 275-282, 2011.
    OpenUrlPubMed
  23. ↵
    1. Xu L,
    2. Li Y,
    3. Sun H,
    4. Zhen X,
    5. Qiao C,
    6. Tian S,
    7. Hou T
    : Current developments of macrophage migration inhibitory factor (MIF) inhibitors. Drug Discov Today 18(11-12): 592-600, 2013.
    OpenUrlPubMed
  24. ↵
    1. Verschoor CP,
    2. Pant SD,
    3. You Q,
    4. Schenkel FS,
    5. Kelton DF,
    6. Karrow NA
    : Single nucleotide polymorphisms alter the promoter activity of bovine MIF. Anim Biotechnol 22(3): 143-150, 2011
    OpenUrlPubMed
    1. Yang D,
    2. Ji HF,
    3. Zhang XM,
    4. Yue H,
    5. Lin L,
    6. Ma YY,
    7. Huang XN,
    8. Fu J,
    9. Wang WZ
    : Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis. Mediators Inflamm 2014: Article ID 890139, 7 pages, 2014.
  25. ↵
    1. Palumbo S,
    2. Bosetti F
    : Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: role of cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids 89(5): 273-278, 2013.
    OpenUrlPubMed
  26. ↵
    1. Sanchooli J,
    2. Ramroodi N,
    3. Sanadgol N,
    4. Sarabandi V,
    5. Ravan H,
    6. Rad RS
    : Relationship between metalloproteinase 2 and 9 concentrations and soluble CD154 expression in Iranian patients with multiple sclerosis. Kaohsiung J Med Sci 30(5): 235-242, 2014.
    OpenUrlPubMed
  27. ↵
    1. Bucala R
    : MIF, MIFAlleles, and Prospects for Therapeutic Intervention in Autoimmunity, J Clin Immunol 33(1): 72-78, 2013.
    OpenUrl
  28. ↵
    1. Benedek G,
    2. Meza-Romero R,
    3. Andrew S,
    4. Leng L,
    5. Burrows GG,
    6. Bourdette D,
    7. Offner H,
    8. Bucala R,
    9. Vandenbark AA
    : Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol 43(5): 1309-1321, 2013.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Hagman S,
    2. Raunio M,
    3. Rossi M,
    4. Dastidar P,
    5. Elovaara I
    : Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study. J Neuroimmunol 234(1-2): 141-147, 2011.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Rinta S,
    2. Airas L,
    3. Elovaara I
    : Is the modulatory effect of pregnancy in multiple sclerosis associated with changes in blood apoptotic molecules? Acta Neurol Scand 122(3): 168-174, 2010.
    OpenUrlPubMed
  31. ↵
    1. Akcali A,
    2. Pehlivan S,
    3. Pehlivan M,
    4. Sever T,
    5. Neyal M
    : Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J Int Med Res 38(1): 69-77, 2010.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Amoli MM,
    2. Garcia-Porrua C,
    3. Ollier WE,
    4. Gonzalez-Gay MA
    : Lack of association between macrophage migration inhibitory factor gene polymorphism and giant cell arteritis. J Rheumatol 32(1): 74-76, 2005.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Amoli MM,
    2. Martin J,
    3. Miranda-Filloy JA,
    4. Garcia-Porrua C,
    5. Ollier WE,
    6. Gonzalez-Gay MA
    : Lack of association between macrophage migration inhibitory factor gene (-173 G/C) polymorphism and cutaneous vasculitis. Clin Exp Rheumatol 24(5): 576-579, 2006.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

In Vivo
Vol. 29, Issue 1
January-February 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lack of Association Between MIF Gene -173G>C Polymorphism with Multiple Sclerosis
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Lack of Association Between MIF Gene -173G>C Polymorphism with Multiple Sclerosis
BETUL CEVIK, SERBULENT YIGIT, NEVIN KARAKUS, DURDANE AKSOY, OMER ATES, SEMİHA KURT
In Vivo Jan 2015, 29 (1) 71-76;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Lack of Association Between MIF Gene -173G>C Polymorphism with Multiple Sclerosis
BETUL CEVIK, SERBULENT YIGIT, NEVIN KARAKUS, DURDANE AKSOY, OMER ATES, SEMİHA KURT
In Vivo Jan 2015, 29 (1) 71-76;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • MIF and D-DT are potential disease severity modifiers in male MS subjects
  • Google Scholar

More in this TOC Section

  • PLLA Coating of Lyophilized Human Bone Allograft for Long-term Release of Antibiotics
  • Association of MMP-11 Genotypes With Colorectal Cancer in Taiwan
  • Acute Cardiovascular Changes Following Cerebral Ischemia in a Non-human Primate Thromboembolic Stroke Model
Show more Experimental Studies

Similar Articles

Keywords

  • multiple sclerosis
  • susceptibility
  • macrophage migration inhibitory factor (MIF)
  • -173G>C gene polymorphism
  • promoter polymorphism
In Vivo

© 2025 In Vivo

Powered by HighWire